#1 Clinical Trials Search in Europe

GEN1078

A groundbreaking first-in-human clinical trial is currently evaluating GEN1078, a promising new drug for patients with malignant solid tumors. This open-label, dose-escalation trial with expansion cohorts aims to assess both the safety profile and preliminary effectiveness of GEN1078 in treating advanced solid cancers. The study focuses on understanding how the body processes the drug, what effects it has on the body, and most importantly, how well it works against solid tumors. For participants in the trial, treatment typically lasts about three months with frequent visits during the initial period. This article provides an overview of the GEN1078 clinical trial and what it means for cancer treatment research.

Table of Contents

What is GEN1078?

GEN1078 is an investigational drug being studied as a potential new treatment for patients with malignant solid tumors (cancers that form a mass or lump in a specific organ or tissue). This medication is currently in the early stages of clinical testing and is not yet approved by regulatory agencies for general use[1].

The drug is being evaluated as a monotherapy, which means it is given alone rather than in combination with other cancer treatments. The ongoing clinical trial is the first time this drug is being tested in humans, what researchers call a first-in-human trial[1].

Clinical Trial Overview

The current study of GEN1078 is an open-label, dose-escalation trial with expansion cohorts. This means all participants receive the actual medication (no placebo) and researchers are testing different dose levels to determine the best dose for future studies[1].

The trial has two main parts:

  • Dose-escalation part: This initial phase determines the safety of different doses and identifies potential side effects[1].
  • Dose-expansion part: Once safe doses are identified, more participants receive the drug at these doses to further assess effectiveness. If two expansion doses are identified, participants will be randomly assigned to one dose or the other[1].

For individual participants, the estimated trial duration is about 8 months, though this may vary. The treatment period itself is expected to last approximately 3 months, also varying by participant[1].

Who Can Participate in the Trial?

This clinical trial is designed for people diagnosed with malignant solid tumors. While the trial information doesn’t specify which particular types of solid tumors are included, this term generally refers to cancers that form solid masses in organs or tissues (as opposed to blood cancers like leukemia)[1].

The specific eligibility criteria (such as age, cancer stage, previous treatments, etc.) are not fully detailed in the available information, but would be explained to potential participants during the screening process[1].

Treatment Process

Participants in the trial receive GEN1078 at specified doses on specified days according to the study protocol. The treatment continues until certain discontinuation criteria are met, which might include disease progression, unacceptable side effects, or other factors determined by the study team[1].

During the first few months of participation, patients can expect frequent clinic visits – either daily or every few days – for monitoring and assessment. These visits allow researchers to closely track how participants are responding to the treatment and monitor for any side effects[1].

Safety Monitoring

A primary goal of this trial is to assess the safety of GEN1078. Researchers are carefully tracking several safety-related outcomes:

  • Dose-limiting toxicities (DLTs): These are side effects serious enough to prevent increasing the dose further. They’re evaluated using standardized criteria from the National Cancer Institute, called Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0[1].
  • Adverse events (AEs): These are any unfavorable and unintended signs, symptoms, or diseases that occur during the trial. Participants are monitored for adverse events from their first dose until 30 days after their last dose[1].
  • Specific immune-related complications: Two particular types of immune reactions – cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) – are being evaluated using criteria from the American Society for Transplantation and Cellular Therapy. CRS is an inflammatory response that can cause fever, low blood pressure, and other symptoms, while ICANS affects the nervous system[1].

How Effectiveness is Being Measured

The trial is evaluating how well GEN1078 works against solid tumors using several measures:

  • Objective Response Rate (ORR): This is the percentage of participants whose cancer shrinks or disappears after treatment. A “confirmed” response means the improvement was seen on more than one assessment. ORR includes participants who achieve either a complete response (disappearance of all target tumors) or partial response (at least 30% decrease in tumor size)[1].
  • Duration of Response (DOR): This measures how long the tumor response lasts, from the first documentation of response until disease progression or death[1].
  • Disease Control Rate (DCR): This is the percentage of participants who achieve complete response, partial response, or stable disease (cancer that is neither growing nor shrinking significantly)[1].
  • Time to Response (TTR): This measures how quickly participants respond to the treatment, calculated from the first day of treatment to the first documentation of objective response[1].

All these measures use standardized criteria called Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, which provides consistent methods for measuring tumor response[1].

How GEN1078 Works in the Body

The trial is studying what happens to GEN1078 in the body after administration, known as pharmacokinetics. This includes:

  • Clearance (CL): How quickly the body removes the drug[1].
  • Volume of Distribution (Vd): How widely the drug spreads throughout body tissues[1].
  • Area Under the Curve (AUC): A measure of the total exposure to the drug over time[1].
  • Maximum Concentration (Cmax): The highest level of drug in the blood[1].
  • Time to Reach Maximum Concentration (Tmax): How long it takes to reach the peak drug level[1].
  • Half-life (t½): How long it takes for half of the drug to be eliminated from the body[1].

Researchers are also monitoring for anti-drug antibodies (ADAs), which are antibodies the body might produce against GEN1078. These could potentially affect how well the drug works or its safety profile[1].

Potential Benefits

As GEN1078 is still in early clinical testing, its benefits are not yet fully understood. The purpose of this trial is to determine whether GEN1078 might be an effective treatment option for patients with solid tumors, and at what dose it should be given[1].

If successful, this trial will help advance GEN1078 to further clinical testing, potentially leading to a new treatment option for cancer patients in the future. However, it’s important to understand that many investigational drugs do not ultimately receive approval, and this research is still in its early stages[1].

Trial Aspect Details
Trial Name First-in-Human, Open-Label, Dose-Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of GEN1078 in Subjects With Malignant Solid Tumors
Drug Being Tested GEN1078
Target Population Patients with malignant solid tumors
Trial Structure Two-part design: dose-escalation phase followed by dose-expansion phase
Trial Duration Approximately 8 months per participant (may vary)
Treatment Duration Approximately 3 months (may vary)
Visit Frequency Daily or every few days during the first few months
Primary Outcomes – Dose Escalation Number of participants with dose-limiting toxicities and adverse events
Primary Outcomes – Dose Expansion Confirmed objective response rate (percentage of patients with complete or partial response)
Secondary Outcomes Pharmacokinetic parameters (how the body processes the drug), anti-drug antibodies, duration of response, disease control rate, time to response
Use of Placebo No placebo; all participants receive active drug
Follow-up Period 30-60 days after last dose for safety assessment, up to approximately 5 years for efficacy outcomes

FAQ

  • What is GEN1078 and what type of cancer is it being tested for? GEN1078 is an investigational drug that is being tested as a potential treatment for malignant solid tumors. The clinical trial is specifically designed for patients with advanced solid cancers. The drug is administered as a monotherapy, meaning it's given alone rather than in combination with other treatments.
  • How is the GEN1078 clinical trial structured? The trial has two main parts: a dose-escalation phase and a dose-expansion phase. In the dose-escalation part, researchers determine the optimal dose by gradually increasing the amount given to participants while monitoring for side effects. In the dose-expansion part, if two effective doses are identified, participants will be randomly assigned to receive either of these doses to further evaluate the drug's effectiveness and safety profile.
  • How long does participation in the GEN1078 trial last? The estimated trial duration for an individual participant is about 8 months, though this may vary for each person. Within this period, the actual treatment with GEN1078 typically lasts about 3 months. During the first few months, participants will need to visit the clinic frequently—sometimes daily or every few days—for monitoring and assessments.
  • What outcomes are the researchers measuring in this trial? In the dose-escalation phase, researchers are primarily measuring side effects and toxicities (called dose-limiting toxicities or DLTs). In the dose-expansion phase, they're measuring the objective response rate (ORR), which is the percentage of patients whose tumors shrink or disappear after treatment. They're also tracking how the body processes the drug (pharmacokinetics), how long responses last, and how quickly patients respond to treatment.
  • Will all participants receive the actual drug or might some receive a placebo? All participants in this trial will receive the active drug GEN1078. No one will be given a placebo. The treatment will continue until certain discontinuation criteria are met, which could include completion of the planned treatment period, disease progression, unacceptable side effects, or other factors determined by the study protocol.

Ongoing Clinical Trials on GEN1078

  • Study on the Safety and Effectiveness of GEN1078 for Patients with Malignant Solid Tumors

    Not recruiting

    1 1
    Investigated drugs:
    Denmark Spain

Glossary

  • Malignant Solid Tumor: A type of cancer that forms a mass of tissue (solid) and has the ability to invade nearby tissues and spread (metastasize) to other parts of the body.
  • First-in-Human Trial: The first time an experimental drug is tested in human subjects, usually after showing promising results in laboratory and animal studies.
  • Open-Label: A type of clinical trial where both the researchers and participants know which treatment is being administered (as opposed to a blinded study where this information is concealed).
  • Dose-Escalation: A study design where the amount of drug given is gradually increased to find the optimal dose that provides benefit with acceptable side effects.
  • Expansion Cohorts: Additional groups of participants added to a clinical trial to further evaluate a specific dose of the drug after the initial dose-finding phase.
  • Monotherapy: Treatment using a single drug, rather than a combination of drugs.
  • Dose-limiting Toxicities (DLTs): Side effects severe enough to prevent further increase of the drug dose or requiring a reduction in dose.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease that develops during treatment, whether or not it is considered related to the treatment.
  • Objective Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Complete Response (CR): The disappearance of all signs of cancer in response to treatment.
  • Partial Response (PR): A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
  • RECIST v1.1: Response Evaluation Criteria in Solid Tumors – a standardized set of rules used to assess how well a cancer patient responds to treatment based on changes in tumor size.
  • Stable Disease (SD): Cancer that is neither growing nor shrinking by a significant amount.
  • Disease Control Rate (DCR): The percentage of patients who have achieved complete response, partial response, or stable disease with treatment.
  • Duration of Response (DOR): The length of time from when a tumor starts to shrink until it begins to grow again.
  • Time to Response (TTR): The time from the start of treatment until the cancer shows a significant response to the treatment.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Clearance (CL): The volume of blood cleared of a drug per unit time, indicating how quickly the body eliminates the drug.
  • Volume of Distribution (Vd): A theoretical measurement of the distribution of a drug between plasma and the rest of the body after dosing.
  • AUC (Area Under the Curve): A measurement of the total exposure to a drug over time, used to determine the overall effect of a particular dosing regimen.
  • Maximum Observed Plasma Concentration (Cmax): The highest concentration of a drug in the blood after it is administered.
  • Terminal Half-life (t½): The time required for the concentration of a drug in the blood to decrease by half.
  • Anti-drug Antibodies (ADAs): Proteins produced by the immune system that recognize and bind to a therapeutic drug, potentially reducing its effectiveness or causing adverse reactions.
  • Cytokine Release Syndrome (CRS): A systemic inflammatory response that can occur as a side effect of certain cancer treatments, causing symptoms like fever, nausea, headache, rash, rapid heartbeat, low blood pressure, and difficulty breathing.
  • Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): A neurological toxicity that can occur with certain cancer treatments, causing symptoms ranging from headache and confusion to seizures and coma.

References

  1. https://clinicaltrials.gov/study/NCT06771921